These outcomes established the role of the circadian control of the NRF2/glutathione pathway for countering fibrotic lung damage, thereby promoting novel chronotherapeutic strategies for the treatment of idiopathic pulmonary fibrosis [83]. The gene discussed is NFE2L2; the disease is pulmonary fibrosis.